Enanta Pharmaceuticals Inc.

ENTA

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions. Next phase2 readout (zelicapavir): Dec 2026. Short interest: 10.5% of float.

BiotechnologyCEO: Jay R. LulyIPO: 2013Website ↗

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

Catalysts

Phase 2Q2 2019EDP-305 Dose 1Non-Alcoholic SteatohepatitisNCT03421431

Primary: Mean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12 (Baseline and Week 12)Enrollment:134/134Sites: 82RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2019EDP-938 Dose 1RSV InfectionNCT03691623

Primary: Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load (Twice daily on Day 2 through Day 11 and once on Day 12)Enrollment:179/179Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2019EDP-305 1 mgPrimary Biliary CholangitisNCT03394924

Primary: Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline (Baseline and Week 12)Enrollment:68/68Sites: 86RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ4 2021EDP-305 1.5 mgNon-Alcoholic SteatohepatitisNCT04378010

Primary: Proportion of Participants Who Achieve ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis and/or Resolution of Steatohepatitis and no Worsening of Liver Fibrosis as Determined by Liver Biopsy (Week 72)Enrollment:98/98Sites: 81RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ1 2022EDP-938Respiratory Syncytial VirusNCT04196101

Primary: Total Symptom Score (TSS) Area Under the Curve (AUC) (Day 1 through Day 14)Enrollment:82/82Sites: 29RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2023EDP-235COVID-19NCT05616728

Primary: Number of Adverse Events as a Measure of Safety and Tolerability (Day 1 through Day 33)Enrollment:231/231Sites: 23RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ2 2023EDP-938Respiratory Syncytial Virus InfectionsNCT04633187

Phase 2Q2 2024EDP-323 Dose Regimen 1RSV InfectionNCT06170242

Phase 2Q3 2024EDP-938Respiratory Syncytial Virus (RSV)NCT04816721

Phase 2Q2 2025EDP-938RSV InfectionNCT05568706

Phase 2Q4 2026zelicapavirRSV Infection, RSV, Respiratory Syncytial Virus (RSV)NCT07482657

Primary: Time to complete resolution of clinical signs of RSV as measured by RESOLVE-P (Day 1 through Day 14)Enrollment:Target 150Sites: 8RANDOMIZED, TRIPLE, TREATMENT

Enanta Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research